The Causes of Parkinson s Disease: Current Theories
|
|
|
- Morris Nichols
- 9 years ago
- Views:
Transcription
1 The Causes of Parkinson s Disease: Current Theories Michael Rezak, M.D., Ph.D. Director, Movement Disorders Center Northwestern Medicine Central DuPage Hospital
2 No. PD Cases Epidemiology and Incidence of Parkinson s Disease (PD) Epidemiology PD is the second most common neurodegenerative disorder after Alzheimer s disease Affects 0.3% of worldwide population 1%-2% of people aged >60 years Approximately 1.5 million people have PD in the United States (US) Men 19.0/100K >women 9.9/100K Prevalence predicted to almost double in US from in individuals aged >50 years Incidence of PD Increases With Aging N= Age 2
3 The Parkinson s Complex Langston JW. Ann Neurol. 2006;59: Adapted with permission from Langston JW. The Parkinson s complex: Parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59(4):
4 Parkinson s Disease Characteristic Motor Deficits 1 Tremor Involuntary tremulous motion Rigidity Stiffness caused by involuntary increase in muscle tone Bradykinesia/akinesia Slowness or absence of movement Postural instability Poor balance, loss of postural reflexes, gait disorder 1 Paulson, Stern. In: Watts, Koller, eds. Movement Disorders
5 Non-Motor PD Features Sleep disorders REM Sleep Behavior Disorder (RBD) Periodic Limb Movements of Sleep (PLMS) Restless Leg Syndrome Sleep Apnea Autonomic dysfunction Neurogenic orthostatic hypotension Bowel and bladder dysfunction Temperature regulation/sweating Cardiac sympathetic denervation Sensory abnormalities Pain, numbness, aching Visual disturbances Dermatological changes Seborrhea Skin cancer Malignant melanoma Olfactory dysfunction Very early sign in PD Cognitive dysfunction Executive dysfunction Dementia Lewy Body disease Psychiatric disorders Affective disorders Depression Euphoria/Mania Psychosis Paranoia Delusions Obsessive Compulsive behaviors
6 Conceptual Diagram of the Phases of PD Increase Disease Onset Diagnosis Nonmotor Symptoms Motor Symptoms Dopaminergic Neurons Decrease Premotor Phase Time (y) Motor Phase Schapira AH et al. Nat Rev Neurol. 2010;6:
7 PD is a 3-Stage Disease Phase 1 Preclinical PD PD-specific pathology assumed to be present Asymptomatic, but will need to be supported by: Molecular markers (α-synuclein, DJ-1, LRRK2, Parkin, PINK1 mutations) Imaging markers (transcranial sonography, PET, SPECT, DaTscan, DTI, MIBG SPECT, α-synuclein imaging) Phase 2 Premotor PD Presence of early nonmotor signs and symptoms due to extranigral PD pathology Nonmotor features commonly occur before the emergence of motor symptoms (olfaction abnormalities; constipation; cardiac involvement; REM sleep behavior disorder; neurobehavioral symptoms) Phase 3 Motor PD PD pathology involves substantia nigra leading to dopamine deficiency sufficient to cause classic motor manifestations followed by later nommotor features Presence of fully established disease (bradykinesia, tremor, rigidity) May progress to include late PD features (dysautonomia, sensory symptoms, cognitive decline) Stern MB, Lang A, Poewe W. Movement Disorders. 2012; 27:54-60
8 Key Concepts in Understanding PD Pathogenesis Lewy Body Neuropathological hallmark of PD Central role of α-synuclein Genetics of PD Mutations impacting mitochondrial function PINK1,DJ-1 Mutations impacting transport of organelles and vesicles SNCA,Tau Mutations impacting degradation pathways Parkin,DJ-1,β-glucocerebrosidase, UCHL1 Mutations impacting reduction in oxidative stress DJ-1 Environmental role in PD Pesticides/herbicides, infectious agents, metals, hydrocarbons Oxidation reactions related to dopamine itself Prion hypothesis Prions are infectious proteins that can cause a group of invariably fatal neurodegenerative diseases by a novel mechanism.
9 Causes of PD PD is heterogeneous Unlikely there is a single etiology Multiple hit hypotheses Contributing factors may include: Environment Genetics Combination of both Abnormal aggregation of α-synuclein may play a key role in the development of PD Progression may relate to prion-like process
10 Lewy Body
11 Cause of PD Still Unknown PD is likely the result of interaction between intrinsic, genetic and environmental causes Some genes and specific mutations associated with PD have been identified Approximately 20% of patients have a family history of PD Majority of PD cases are sporadic (also known as idiopathic) in nature Intrinsic Genetics Environment Dopamine and Oxidative Stress Dopamine interaction with Alpha synuclein Dopamine cells and Calcium influx Rural living, and exposure to environmental toxins, such as pesticides, may contribute to the development of PD No single environmental cause of PD has been determined Personal habits, including smoking cigarettes and drinking coffee, appear to be associated with a lower risk of PD Coppede F. Sci World J. 2012;2012:1-12. Article National Human Genome Research Institute. Learning About Parkinson s Disease. Available at: Tanner CM. Mov Disord. 2010;25(suppl 1):S58-S62. 11
12 Any Relative PD 1st Degree Rel PD Family History- Tremor Constipation Mood Disorder Pesticide Exposure Head Injury Rural Residence Beta Blockers Farming/ Agriculture Well Water CCBs Alcohol NSAIDs Past Smokers Hypertension Coffee Ever Smoked Current Smokers Risk Factors for PD CCB indicates calcium channel blocker; NSAID, nonsteroidal anti-inflammatory drug. Noyce AJ et al. Ann Neurol [Accepted]. doi: /ana
13 Environmental Relationships
14 Northern California in 1980 s
15 MPTP
16 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine (MPTP) Northern California neurotoxic designer drug resulted in an epidemic of Parkinson s disease in early 1980 s Clearly documented a role for environmental toxins in Parkinsonism-provided primate model of PD MPTP crosses the BBB and is converted to MPP+ by MAO-B which is taken up by dopamine neurons destroying complex I in mitochondria depleting ATP MPP+ is very similar to herbicide paraquat and isoquinoline derivatives that are ubiquitous in our environment
17 MPTP MPP+
18 Environmental Factors in the Etiology of Parkinson s Disease Pesticides Most consistent data on environmental cause Exposure increases risk by almost 2 fold Mitochondrial damage Rotenone Animal models Paraquat Maneb Ubiquitin-proteosomal inhibition Ziram
19 Environmental Factors in the Etiology of Parkinson s Disease Infectious Agents Entry via nasal or GI portal may explain sites of early involvement H5N1 avian influenza virus Phosphorylation and aggregation of alpha synucleinc Epstein Barr virus May trigger intracellular protein aggregation Parkinsonism Coxsackie virus Japanese encephalitis B West Nile virus HIV Prions
20 Cigarettes
21 Cigarette Smoking Consistent inverse relationship for PD incidence 50% decreased risk. Dose response relationship Animal models demonstrates nicotine protection of mitochondria Nicotine reduces MAO-B activity Pyridines may inhibit uptake of toxic molecules such as pesticides and MPTP
22 Caffeine
23 Caffeine Caffeine consumption before PD is associated with reduced risk of PD (coffee, tea, caffeinated beverages) There is an inverse dose response relationship 5X risk reduction for >24 oz coffee per day Caffeine blocks Adenosine A2A receptors (excitotoxic mediated cell death) Adenosine A 2A antagonists have been shown to reduce MPTP related dopamine neuronal damage in the substantia nigra A 2A antagonism may explain benefits of caffeine
24 Dietary Considerations Increased risk associated with high amounts of dietary iron in combination with high manganese content Possible relationship between low folate levels and elevated homocysteine levels Vitamin D deficiency (common in PD) may have relationship to cognitive impairment B12 deficiency can contribute to numerous neurological deficits
25 Other Environmental Factors Uric acid levels associated with slower rate of progression of PD Head trauma increases risk of developing PD Milk consumption raises risk of developing PD? Occupational risk is greatest and most consistent in farming communities Amish in Northeast US-6% prevalence
26 Internal Environmental Contributions Dopamine can induce oxidative stress Auto-oxidation can result in free radical generation Cells defense is to turn oxidized products into insoluble neuromelanin -reflecting cells with most oxidative stress Dopamine interaction with abnormal α-synuclein enhances permeability of synaptic vesicle membranes thereby allowing increased leakage of dopamine into cell body resulting in more oxidation and damage Interaction between α-synuclein, calcium and dopamine is required to maintain cell integrity
27 Genetics of PD At least 14 genetic abnormalities identified AD AR-susceptibility genes Genetic mutations code for a variety of cellular functions, all of which can lead to cell death Multiple genotypes, similar phenotype
28 Genetics and PD PD is primarily a sporadic or idiopathic disorder The Human Genome Project has helped to better define the gene association Up to 20% of patients with PD have the familial variety Causal and susceptibility genes discovered for PD Monogenic forms (autosomal dominant) account for only a very small portion of patients with PD The younger the patient (<50), the more likely there is a genetic component Genetic abnormalities disrupt vital cellular functions (mitochondria, ubiquitin-proteosome system, excessive/abnormal protein production)
29 Genes Identified in Familial PD Name SNCA (PARK1, PARK4) AD/A R Prevalence Lewy Bodies Protein Function Causal Genes and Loci AD Very rare LB Vesicle trafficking LRRK2 (PARK8) AD 5% familial Caucasian; 1%-2% of sporadic cases PRKN (PARK2) AR Most prevalent in early-onset (<45 years) but relatively uncommon PINK1 (PARK6) AR Rare cause of recessively inherited, early-onset Parkinsonism LB Nigral degeneration; rare LB Unavailable Cytoplasmic kinase Ubiquitin E3 Ligase Mitochondrial kinase UCHL1 (PARK5) AD Mean onset: 50 LB Removes polyubiquitin DJ-1 (Park 7) AR Early onset LB? Peroxiredoxin (antioxidant) GBA AD Slightly younger onset LB? Β-glucocerbrosidase
30 LRRK2 Associated with familial and idiopathic PD Large, multidomain protein Autosomal dominant Most prevalent gene associated with PD Among Caucasian patients Up to 5% of familial cases 1%-2% of idiopathic cases Its physiolgic function and its role in PD etiology are unclear May have a role in lysosomal pathways Tofaris GK. Mov Disord. 2012;27: Wider C et al. Mov Disord. 2010;25(suppl 1):S15 S20.
31 PARK2: Parkin Autosomal recessive Juvenile Parkinsonism Significance Gene most commonly found in early onset Up to 50% of recessive familial patients <45 years express mutation Onset age range Lewy bodies not a characteristic Positive response to L-dopa Coppede F. The Scientific World Journal, 2012, Article ID , 12 pages. doi: /2012/ Wider C. Mov Disord. 2010;25(suppl 1):S15 S20.
32 SNCA: a-synuclein -The first gene associated with PD (1997) -Autosomal dominant -Causal gene -Critical mutations or overproduction of a--synuclein causes misfolding of the protein and subsequent accumulation, resulting in cell toxicity -Linked to both familial and idiopathic PD -Altered the course of research to focus on genetics -originally linked to early onset PD -PD related to SNCA mutations are very rare Originally linked with early onset (40s) PD due to SNCA mutations is very rare Brockmann K et al. Encyclopedia of Life Sciences (ELS) doi: / a Coppede F. The Scientific World Journal, vol 2012, Article ID , 12 pages. doi: /2012/ Lesage S et al. Hum Mol Genet. 2009;18:R48-R59. Olanow CW et al. Neurology. 2009;72(21 suppl 4):S1-S136. Stefanis L. Cold Spring Harb Perspect Med. 2012;2:1-23. Wider C. Mov Disord. 2010;25(suppl 1):S15 S20.
33 What Is α-synuclein? A protein primarily expressed in neural tissue Main function of α-synuclein may be the control of neurotransmitter release Abnormal configuration is associated with the development of PD α-synuclein is the main component of Lewy bodies Disrupts synaptic messaging Level of causality in PD is not clear α-synuclein toxicity is considered a possible therapeutic target PD Brockmann K et al. Encyclopedia of Life Sciences (ELS) doi: / a Stefanis L. Cold Spring Harb Perspect Med. 2012;4:a
34 α-synuclein
35 Prion Hypothesis
36 α-synuclein and the Prion Hypothesis Prion diseases Misfolded proteins induce misfolding of other proteins with which they come in contact (templating), resulting in a chain reaction leading to cell toxicity and progression of PD Postmortem evidence Lewy bodies containing α-synuclein in embryonic dopaminergic cell transplants suggesting prion-like transmission Other prion-like PD characteristics Accelerated protein production Proteins not cleared properly Transmissible from cell to cell and between animals Hilker R et al. BMC Neurology. 2011;11:74. Olanow CW et al. Proc Nat Acad Sci USA.2009;106:
37 What Is The Role of Abnormal α-synuclein Aggregation in PD? Braak Hypothesis Spread of Lewy bodies as PD progresses Lewy bodies (abnormal aggregations of α-synuclein) are a prerequisite for postmortem PD diagnosis Braak and colleagues hypothesize that Lewy bodies spread throughout the brain in a predictable pattern as PD progresses Pathologic studies in PD patients have found Lewy pathology in brain, cardiac, and enteric autonomic nervous systems It is not known whether α-synuclein aggregation is a direct causative factor in the pathogenesis of PD or a protective mechanism against protein-induced cell toxicity Braak H et al. Cell Tissue Res. 2004;318: Fortin DL et al. Mov Disord. 2010;25(suppl 1):S Hawkes CH et al. Parkinsonism Relat Disord. 2010;16: Wider C et al. Mov Disord. 2010;25:S15-S20. Adaptation of figure reprinted with kind permission from Springer Science+Business Media: Cell Tissue Res, Stages in the development of Parkinson's disease-related pathology, 318, 2004, page 122, by Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K, Figure 1. Copyright 2004 Springer Berlin Heidelberg.
38 α-synuclein as a Prion
39 Mottos To Live By in PD Never eat at a diner named Joe s Greasy Spoon Never cheer for the opposing team at Wrigley Field Never obtain Parkinson s disease advice from a Starbucks barista (or the internet) Never become complacent about Parkinson s disease Always surround yourself with an outstanding interdisciplinary team
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,
Chapter 28. Drug Treatment of Parkinson s Disease
Chapter 28 Drug Treatment of Parkinson s Disease 1. Introduction Parkinsonism Tremors hands and head develop involuntary movements when at rest; pin rolling sign (finger and thumb) Muscle rigidity arthritis
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia
Parkinson's s disease - a
Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability
Dementia & Movement Disorders
Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia
Unmet Needs for Parkinson s Disease Therapeutics
Unmet Needs for Parkinson s Disease Therapeutics Coalition Against Major Diseases & FDA Workshop October 20, 2014 Caroline M Tanner MD, PhD Director, Parkinson's Disease Research Education and Clinical
Parkinson's disease. Definition. Symptoms
Parkinson's disease Definition Parkinson's disease is a progressive disorder of the nervous system that affects your movement. It develops gradually, sometimes starting with a barely noticeable tremor
Journal Club. Parkinsonismo iatrogeno
PROGETTO UNIVA 2013 Journal Club Parkinsonismo iatrogeno Pietro Gareri, MD, PhD Geriatra ASP Catanzaro Lamezia Terme 3 Luglio 2013 Drug-induced parkinsonism (DIP) was recognized in the early 1950s as a
Lewy body dementia Referral for a Diagnosis
THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia
SLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
Parkinson s Disease: A Review of Motor and Nonmotor Symptoms
Diana Hong Parkinson s Disease: A Review of Motor and Nonmotor Symptoms Abstract: Although Parkinson s disease (PD) is considered a motor system disorder caused by the degeneration of dopaminergic neurons
Amino Acid Therapy to Restore Neurotransmitter Function
Amino Acid Therapy to Restore Neurotransmitter Function Alvin Stein, MD Neurotransmitters are chemicals manufactured by our bodies that allow our nervous system to function properly. When the body requires
Alzheimer s disease. What is Alzheimer s disease?
Alzheimer s disease What is Alzheimer s disease? What we know about dementia and Alzheimer s disease Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease Outline of Today s Lecture Why is Alzheimer s disease a problem? What is Alzheimer s Disease? What causes Alzheimer s disease? How can
Parkinson s Disease (PD)
Parkinson s Disease (PD) Parkinson s disease (PD) is a movement disorder that worsens over time. About 1 in 100 people older than 60 has Parkinson s. The exact cause of PD is still not known, but research
Alcohol and Brain Damage
Alcohol and Brain Damage By: James L. Holly, MD O God, that men should put an enemy in their mouths to steal away their brains! That we should, with joy, pleasance, revel, and applause, transform ourselves
Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders
Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders Karen Frei, Erik Ch. Wolters Abstract: The twentieth World Congress on Parkinson s Disease and Related Disorders was held
Multiple System Atrophy
Multiple System Atrophy U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Multiple System Atrophy What is multiple system atrophy? Multiple system atrophy
FUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov
FUNCTIONAL EEG ANALYZE IN AUTISM Dr. Plamen Dimitrov Preamble Autism or Autistic Spectrum Disorders (ASD) is a mental developmental disorder, manifested in the early childhood and is characterized by qualitative
1: Motor neurone disease (MND)
1: Motor neurone disease (MND) This section provides basic facts about motor neurone disease (MND) and its diagnosis. The following information is an extracted section from our full guide Living with motor
CAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
Management in the pre-hospital setting
Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,
PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.
PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common
III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases
III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2.1. Multiple System Atrophy (MSA) MSA is a sporadic, adult onset degenerative neurological
Parkinson s Disease Symptoms Guide
Parkinson s Disease Symptoms Guide Some symptoms of Parkinson s disease (PD) are hard for even specialists to detect. Others are obvious even to an untrained eye. Parkinson s symptoms are different for
NEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON. created by Dr. Joanne Hsu
NEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON NEURON AND NEURAL TRAMSMISSION: MICROSCOPIC VIEW OF NEURONS A photograph taken through a light microscope (500x) of neurons in the spinal cord. NEURON
Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm)
Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm) Accessing information on Multiple System Atrophy (MSA) can be hard work. The Sarah Matheson Trust (SMT) produces a guide to MSA that
Drugs, The Brain, and Behavior
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major categories
J/601/2874. This unit must be assessed in accordance with Skills for Care and Development s QCF Assessment Principles.
Unit 13: Dementia Awareness Unit code: DEM 201 Unit reference number: J/601/2874 QCF level: 2 Credit value: 2 Guided learning hours: 17 Unit summary The aim of the unit is to enable learners to gain knowledge
Clinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved
Clinical and Therapeutic Cannabis Information Written by Cannabis Training University (CTU) All rights reserved Contents Introduction... 3 Chronic Pain... 6 Neuropathic Pain... 8 Movement Disorders...
PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB
PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety
Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline)
EMA/744222/2014 Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline) This is a summary of the risk management plan (RMP) for Rasagiline ratiopharm, which details the measures
Social Security Disability Insurance and young onset dementia: A guide for employers and employees
Social Security Disability Insurance and young onset dementia: A guide for employers and employees What is Social Security Disability Insurance? Social Security Disability Insurance (SSDI) is a payroll
Motor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia
Motor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia A group of subcortical nuclei caudate, putamen, globus pallidus Caudate & Putamen = Neostriatum caudate
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human
Intellectual Symptoms Amnesia: Loss of memory function
Definition of Dementia (de mens) Latin for out of mind Permanent loss of multiple intellectual functions Alois Alzheimer first described this disease in 1906 in a brain specimen from an autopsy. Alzheimer
Learning Disabilities, Behavioral/Emotional Disorders, and Other Brain Disorders: What We Know
Learning Disabilities, Behavioral/Emotional Disorders, and Other Brain Disorders: What We Know by Ted Schettler, MD There are many ways that something can go awry in the brain, which can impair our ability
Parkinson s Disease: Factsheet
Parkinson s Disease: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Parkinson s disease (PD) is a progressive neuro-degenerative condition that affects a person s
Parkinson s prevalence in the United Kingdom (2009)
Parkinson s prevalence in the United Kingdom (2009) Contents Summary 3 Background 5 Methods 6 Study population 6 Data analysis 7 Results 7 Parkinson's prevalence 7 Parkinson's prevalence among males and
INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
William Shaw, Ph.D. The Great Plains Laboratory, Inc., Lenexa, Kansas, USA
Inhibition of dopamine conversion to norepinephrine by Clostridia metabolites appears to be a (the) major cause of autism, schizophrenia, and other neuropsychiatric disorders. All these factors can now
PARTNERS IN PARKINSON S. Parkinson s Disease Guide
PARTNERS IN PARKINSON S Parkinson s Disease Guide Each individual travels his or her own journey with Parkinson s disease, often encountering new challenges as symptoms progress and care needs change.
Introduction to Psychology, 7th Edition, Rod Plotnik Module 3: Brain s Building Blocks. Module 3. Brain s Building Blocks
Module 3 Brain s Building Blocks Structure of the Brain Genes chains of chemicals that are arranged like rungs on a twisting ladder there are about 100,000 genes that contain chemical instructions that
Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault [email protected]
Mental health issues in the elderly January 28th 2008 Presented by Éric R. Thériault [email protected] Cognitive Disorders Outline Dementia (294.xx) Dementia of the Alzheimer's Type (early and late
Alzheimer Disease (AD)
1 Alzheimer Disease (AD) 2 Alzheimer's disease is a progressive degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. It was first described by Dr. Alois Alzheimer
Index. misfolded proteins in immune activation, 384 385 pathogenic effects cytoskeleton, 74 75
A AADC. See Aromatic amino acid decarboxylase AAV. See Adeno-associated virus Acetylcholine (ACh), functional imaging, 174 175 ACh. See Acetylcholine Adaptive immune system central nervous system, 381
GENOMICS: REINVIGORATING THE FIELD OF PSYCHIATRIC RESEARCH
Office of Communications www.broadinstitute.org T 617-714-7151 [email protected] 7 Cambridge Center, Cambridge, MA 02142 GENOMICS: REINVIGORATING THE FIELD OF PSYCHIATRIC RESEARCH For decades,
CHAPTER- 6. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. 1. Introduction. 2. Methods
CHAPTER- 6 Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats 1. Introduction Neurodegenerative disorders, such as AD are often characterized by the degeneration of the
Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
Methyl groups, like vitamins, are
Methyl groups are essential for the body to function properly and must be obtained from the diet The need for methyl groups increases under stress Chapter 11 Betaine a new B vitamin Methyl groups reduce
Parkinson s Disease - A Junior Doctor s Survival Guide
Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna
Genetic Mutations. Indicator 4.8: Compare the consequences of mutations in body cells with those in gametes.
Genetic Mutations Indicator 4.8: Compare the consequences of mutations in body cells with those in gametes. Agenda Warm UP: What is a mutation? Body cell? Gamete? Notes on Mutations Karyotype Web Activity
Cerebral palsy can be classified according to the type of abnormal muscle tone or movement, and the distribution of these motor impairments.
The Face of Cerebral Palsy Segment I Discovering Patterns What is Cerebral Palsy? Cerebral palsy (CP) is an umbrella term for a group of non-progressive but often changing motor impairment syndromes, which
Liver Function Essay
Liver Function Essay Name: Quindoline Ntui Date: April 20, 2009 Professor: Dr. Danil Hammoudi Class: Anatomy and Physiology 2 Liver function The human body consist of many highly organize part working
Patients with dementia and other types of structural brain injury are predisposed to delirium (i.e., abrupt onset, temporary confusion caused by
Dementia is the permanent loss of multiple intellectual functions resulting from neuronal death. Dementia afflicts 10% of individuals over the age of 65 and these patients survive approximately seven years
THEORIES OF NEUROLOGICAL AGING AND DEMENTIA
THEORIES OF NEUROLOGICAL AGING AND DEMENTIA Aging Overview The primary care physician must advise middle-age and older patients about ways to age successfully. Dementia is a common disabling illness that
Management of Parkinson s Disease in Primary Care
Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo
How To Find Out If The Gulf War And Health Effects Of Serving In The Gulf Wars Are Linked To Health Outcomes
Gulf War and Health: Update of Health Effects of Serving in the Gulf War Statement of Stephen L. Hauser, M.D. Professor and Chair of Neurology University of California, San Francisco, School of Medicine
Management of Fibromyalgia: Rationale for the use of Magnesium and Malic Acid. Journal of Nutritional Medicine
Management of Fibromyalgia: Rationale for the use of Magnesium and Malic Acid 1 Journal of Nutritional Medicine Guy E. Abraham MD and Jorge D. Flechas MD, MPH FROM ABSTRACT: Primary Fibromyalgia (FM) is
Incidence, Risk and Prognosis of Parkinson Disease
Incidence, Risk and Prognosis of Parkinson Disease Acknowledgements This study was supported by a grant (015.000.083) of the Netherlands Organization for Scientific Research (NWO). The Rotterdam Study
MOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP
MOTION AND E-MOTION Andrea Cavanna MD PhD FRCP Consultant in Behavioural Neurology, BSMHFT, Birmingham, UK Hon Professor in Neuropsychiatry, Aston University, Birmingham, UK Hon Reader in Neuropsychiatry,
CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE
CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE Charbel MACARI Physical Therapist, AUBMC Master in Neurological Rehabilitation OUTLINE Definition, Epidemiology and
Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD
Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the
INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
Emergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.
High Prevalence and Incidence Prevalence 85% of Americans will experience low back pain at some time in their life. Incidence 5% annual Timothy C. Shen, M.D. Physical Medicine and Rehabilitation Sub-specialty
PATIENT HISTORY FORM
PATIENT HISTORY FORM If you are new to the office, have not been seen in over one (1) year, or are returning for a new problem, please complete this form in full. If there have been any changes since your
Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs)
Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs) Single nucleotide polymorphisms or SNPs (pronounced "snips") are DNA sequence variations that occur
1. Give the name and functions of the structure labeled A on the diagram. 2. Give the name and functions of the structure labeled B on the diagram.
2013 ANATOMY & PHYSIOLOGY Sample Tournament Station A: Use the diagram in answering Questions 1-5. 1. Give the name and functions of the structure labeled A on the diagram. 2. Give the name and functions
PRESCRIPTION DRUG ABUSE prevention
PRESCRIPTION DRUG ABUSE prevention Understanding Drug Addiction Many people do not understand how someone could abuse drugs even when their life seems to be falling apart. It is often assumed that those
How to identify, approach and assist employees with young onset dementia: A guide for employers
How to identify, approach and assist employees with young onset dementia: A guide for employers What is dementia? Dementia involves the decline of cognitive functions. Young Onset Dementia, also known
Overactive bladder is a common condition thought to. women, and is a serious condition that can lead to. significant lifestyle changes.
Overactive bladder is a common condition thought to FADE UP TO WIDE SHOT OF FEMALE MODEL WITH TRANSPARENT SKIN. URINARY BLADDER VISIBLE IN PELVIC REGION affect over 16 percent of adults. It affects men
How To Treat An Elderly Patient
1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity
Electrohypersensitivity and multiple chemical sensitivity: two clinicbiological. disorder?
5 th Paris Appeal Congress, 18th of May, 2015 Royal Academy of Medicine, Belgium IDIOPATHIC ENVIRONMENTAL INTOLERANCE: WHAT ROLE FOR ELECTROMAGNETIC FIELDS AND CHEMICALS? Electrohypersensitivity and multiple
Nutrition and Parkinson s Disease: Can food have an impact? Sarah Zangerle, RD, CD Registered Dietitian Froedtert Memorial Lutheran Hospital
Nutrition and Parkinson s Disease: Can food have an impact? Sarah Zangerle, RD, CD Registered Dietitian Froedtert Memorial Lutheran Hospital Importance of Nutrition & Parkinson s Disease Good nutrition
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects
How To Know If You Have Parkinsonian Syndrome
Ministry of Defence Synopsis of Causation Parkinson s Disease Author: Dr David Jenkins, Medical Author, Medical Text, Edinburgh Validator: Dr Christopher Martyn, Southampton General Hospital, Southampton
Genetics BRCA1 and BRCA2 are gene mutations which give 5 percent genetic risk of breast and ovary cancers. Worse if they drink alcohol.
Cancer seminar Ginseng & Dang Gui 10 Chinese formula to help cancer patients with energy. Cell Protect Green tea and turmeric increases efficacy as it helps cancer drugs to stay in cell i.e. reduce drug
Glutathione and Oxidative Stress - Part I
Glutathione and Oxidative Stress - Part I By: James L. Holly, MD Oxidative Stress refers to effects from endogenous (produced in the body) toxins (free radicals) produced in the body by normal metabolism
Disorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis
Disorders Considered A Brief Synopsis of Select Neurological Disorders Four neurological disorders are examined to illustrate pathological conditions that can develop related to course material Myasthenia
Coenzyme Q10. Information Sheet
Coenzyme Q10 What is Coenzyme Q10? Coenzyme Q10 (or CoQ10) is a substance present in every cell of the body. A coenzyme is a very small molecule that enhances the function of enzymes, particularly in the
Treatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
Alzheimer's: The Latest Assessment and Treatment Strategies
Questions from chapter 1 Alzheimer's: The Latest Assessment and Treatment Strategies 1) What is a loss of cognitive and intellectual powers without changes in consciousness. a) dementia b) delusions c)
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,
The diagram below summarizes the effects of the compounds that cells use to regulate their own metabolism.
Regulation of carbohydrate metabolism Intracellular metabolic regulators Each of the control point steps in the carbohydrate metabolic pathways in effect regulates itself by responding to molecules that
